What is the prevalence of Mastocytosis and MCAS?

The prevalence of Mastocytosis is estimated to be between 1 in 10,000 and 1 in 20,000 individuals, while the prevalence of Mast Cell Activation Syndrome (MCAS) remains largely unknown due to the lack of standardized diagnostic criteria and clinical underreporting.

Epidemiology and Prevalence Challenges

Mastocytosis is classified as a rare disease, though it is often considered the most common disorder of mast cell accumulation. Because MCAS is a newer diagnostic entity, epidemiological data for Mast Cell Activation Syndrome is significantly more limited than that of Mastocytosis. Obtaining accurate figures for both conditions is hindered by frequent misdiagnosis or underdiagnosis, as symptoms often mimic common allergic or gastrointestinal disorders.

Demographics and Onset

Mastocytosis presents in two distinct peaks: a pediatric form (typically cutaneous mastocytosis) that often resolves after puberty, and an adult-onset form (systemic mastocytosis) that is usually chronic and lifelong. Gender distribution in Mastocytosis is generally equal, though some studies suggest a slight male predominance in certain systemic subtypes. In contrast, MCAS is frequently reported in clinical settings with a higher prevalence in adult females, though it is unclear if this reflects true biological susceptibility or differences in healthcare-seeking behavior.

Global Perspective and Real-World Data

There are no significant geographic or ethnic variations currently established in the literature, likely due to a lack of large-scale, cross-population screening. At DiseaseMaps.org, our community of 593 individuals living with Mastocytosis and MCAS provides a vital, real-world lens into the patient experience. This community data reflects the diagnostic journey that many patients face, highlighting that while clinical texts provide estimates, the lived reality of those with Mastocytosis and MCAS often involves years of searching for a definitive diagnosis. By mapping these experiences, we can better understand the true burden of Mastocytosis and MCAS beyond what is documented in traditional medical registries.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• Orphanet (ORPHA: 569) - Mastocytosis


• NIH Genetic and Rare Diseases Information Center (GARD) - Mast Cell Activation Syndrome


• The Mast Cell Disease Society (TMS) - Patient Statistics and Advocacy